Edit
Tenpoint Therapeutics Ltd
https://www.tenpointtherapeutics.com/Last activity: 02.02.2026
Active
Tenpoint Therapeutics is a vision-restoring engineered cell-based therapeutics company. We are embracing a new opportunity to fundamentally reshape the future for people with ocular diseases. We have an ambitious goal with global impact.
Location: United Kingdom
Employees: 11-50
Total raised: $317.72M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 31.10.2023 | British Pa... | britishpat... |
| 28.01.2023 | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.01.2026 | Series B | $235M | Janus Hend... |
| 13.07.2023 | - | $12.72M | British Pa... |
| 13.07.2023 | Series A | $70M | Sofinnova ... |
Mentions in press and media 13
| Date | Title | Description |
| 02.02.2026 | Tenpoint Therapeutics Secures $235M, Prepares YUVEZZI Launch for Presbyopia | Tenpoint Therapeutics secured $235 million in new capital. This robust funding fuels the impending launch of YUVEZZI. YUVEZZI is an FDA-approved, first-of-its-kind dual-agent eye drop. It targets presbyopia, a widespread aging vision condit... |
| 30.01.2026 | Tenpoint Therapeutics: $235 Million Raised To Launch YUVEZZI Presbyopia Eye Drop | Tenpoint Therapeutics has secured $235 million in new funding to support the planned commercialization of its presbyopia treatment, YUVEZZI. The company said the capital combines an $85 million Series B preferred stock financing and a $150 ... |
| 29.01.2026 | Top Startup and Tech Funding News – January 29, 2025 | It’s Thursday, January 29, 2026, and we’re back with today’s top startup and tech funding news. Today’s deals reflect deepening investor commitment to AI cloud infrastructure, chiplet interconnects, fintech orchestration, and scalable biote... |
| 29.01.2026 | Tenpoint Therapeutics Raises $235M Through Series B and Credit Facility | Tenpoint Therapeutics, Ltd., a London, UK and Seattle, WA-based provider of vision rejuvenation treatments for the aging eye, raised $235m through a Series B stock financing and a credit facility. The company raised $85m in Series B financi... |
| 29.01.2026 | Tenpoint Therapeutics: $235 Million Raised To Launch Dual Agent Presbyopia Eye Drop YUVEZZI | Tenpoint Therapeutics said it has secured $235 million in new capital, combining an $85 million Series B preferred stock financing with a $150 million senior secured term loan facility, as the company prepares to commercialize its newly app... |
| 12.12.2024 | Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines | The company will file the NDA for BRIMOCHOL™ PF, a once-a-day eye drop for the treatment of presbyopia, with a goal of US commercial launch in 1H, 2026 Merger initiates Crossover Financing Round with participation from syndicate members inc... |
| 21.08.2024 | Glenmark and SalioGen: A New Era in Ophthalmic Treatments | In the bustling world of pharmaceuticals and biotechnology, two companies are making waves in the ophthalmic sector. Glenmark Therapeutics Inc. and SalioGen Therapeutics are not just players; they are pioneers. Their recent announcements re... |
| 19.08.2024 | SalioGen Therapeutics Appoints Kali Stasi, M.D., Ph.D. as Chief Medical Officer | -Dr. Stasi brings to SalioGen 30 years of experience in ophthalmology and genetic medicine- LEXINGTON, Mass., Aug. 19, 2024 /PRNewswire/ -- SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on... |
| 31.07.2024 | From labs to market: 10 promising biotech startups based in the UK | Biotechnology, or biotech, uses living organisms to create products and technologies that improve our lives. This field spans not only healthcare but also sectors such as agriculture, environmental protection, and industrial processes, lead... |
| 13.07.2023 | British Patient Capital invests £10m in Tenpoint Therapeutics | 12 July 2023: British Patient Capital has invested £10m in Tenpoint Therapeutics, an engineered cell-based therapeutics and in vivo reprogramming company developing breakthrough regenerative treatments for ocular diseases, as part of a $70 ... |
Show more